PCOS Renamed to PMOS for Better Health Representation

The condition formerly known as Polycystic Ovary Syndrome (PCOS) has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to more accurately represent its complex health effects. This renaming process was led by Professor Helena Teede from Monash University and involved contributions from 50 medical professionals and organizations, including the Endocrine Society.

The decision follows a comprehensive global review that gathered 22,000 survey responses and included workshops with patients and multidisciplinary health experts. The previous terminology contributed to misconceptions about the condition, primarily focusing on ovarian cysts, despite evidence showing that abnormal cysts are not always present.

The new name aims to improve awareness, diagnosis, and treatment for women affected by the condition, with a full implementation of the changes expected by 2028. Professor Terhi Piltonen from Oulu University emphasized the importance of cultural sensitivity in the renaming process, while Rachel Morman from Verity PCOS UK expressed optimism that the new name will lead to better recognition of the hormonal and metabolic dimensions of the condition.